192 related articles for article (PubMed ID: 17283174)
1. Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling.
Ji Q; Chang L; Stanczyk FZ; Ookhtens M; Sherrod A; Stolz A
Cancer Res; 2007 Feb; 67(3):1361-9. PubMed ID: 17283174
[TBL] [Abstract][Full Text] [Related]
2. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men.
Blouin K; Richard C; Brochu G; Hould FS; Lebel S; Marceau S; Biron S; Luu-The V; Tchernof A
J Endocrinol; 2006 Dec; 191(3):637-49. PubMed ID: 17170221
[TBL] [Abstract][Full Text] [Related]
3. Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism.
Ji Q; Chang L; VanDenBerg D; Stanczyk FZ; Stolz A
Prostate; 2003 Mar; 54(4):275-89. PubMed ID: 12539226
[TBL] [Abstract][Full Text] [Related]
4. Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling.
Ji Q; Aoyama C; Nien YD; Liu PI; Chen PK; Chang L; Stanczyk FZ; Stolz A
Cancer Res; 2004 Oct; 64(20):7610-7. PubMed ID: 15492289
[TBL] [Abstract][Full Text] [Related]
5. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
6. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells.
Rizner TL; Lin HK; Peehl DM; Steckelbroeck S; Bauman DR; Penning TM
Endocrinology; 2003 Jul; 144(7):2922-32. PubMed ID: 12810547
[TBL] [Abstract][Full Text] [Related]
7. Partitioning of 5alpha-dihydrotestosterone and 5alpha-androstane-3alpha, 17beta-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation.
Nunlist EH; Dozmorov I; Tang Y; Cowan R; Centola M; Lin HK
J Steroid Biochem Mol Biol; 2004 Jul; 91(3):157-70. PubMed ID: 15276623
[TBL] [Abstract][Full Text] [Related]
8. Role of human type 3 3alpha-hydroxysteroid dehydrogenase (AKR1C2) in androgen metabolism of prostate cancer cells.
Rizner TL; Lin HK; Penning TM
Chem Biol Interact; 2003 Feb; 143-144():401-9. PubMed ID: 12604227
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid-induced androgen inactivation by aldo-keto reductase 1C2 promotes adipogenesis in human preadipocytes.
Veilleux A; Côté JA; Blouin K; Nadeau M; Pelletier M; Marceau P; Laberge PY; Luu-The V; Tchernof A
Am J Physiol Endocrinol Metab; 2012 Apr; 302(8):E941-9. PubMed ID: 22275760
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.
Lin HK; Steckelbroeck S; Fung KM; Jones AN; Penning TM
Steroids; 2004 Dec; 69(13-14):795-801. PubMed ID: 15582534
[TBL] [Abstract][Full Text] [Related]
13. Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer.
Bauman DR; Steckelbroeck S; Peehl DM; Penning TM
Endocrinology; 2006 Dec; 147(12):5806-16. PubMed ID: 16959841
[TBL] [Abstract][Full Text] [Related]
14. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
15. The effect of allelic variation in aldo-keto reductase 1C2 on the in vitro metabolism of dihydrotestosterone.
Takahashi RH; Grigliatti TA; Reid RE; Riggs KW
J Pharmacol Exp Ther; 2009 Jun; 329(3):1032-9. PubMed ID: 19258517
[TBL] [Abstract][Full Text] [Related]
16. 5alpha-Androstane-3alpha,17beta-diol activates pathway that resembles the epidermal growth factor responsive pathways in stimulating human prostate cancer LNCaP cell proliferation.
Zimmerman RA; Dozmorov I; Nunlist EH; Tang Y; Li X; Cowan R; Centola M; Frank MB; Culkin DJ; Lin HK
Prostate Cancer Prostatic Dis; 2004; 7(4):364-74. PubMed ID: 15452555
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking simulations of steroid substrates into human cytosolic hydroxysteroid dehydrogenases (AKR1C1 and AKR1C2): insights into positional and stereochemical preferences.
Jin Y; Penning TM
Steroids; 2006 May; 71(5):380-91. PubMed ID: 16455123
[TBL] [Abstract][Full Text] [Related]
18. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
19. Androgen metabolism in adipose tissue: recent advances.
Blouin K; Veilleux A; Luu-The V; Tchernof A
Mol Cell Endocrinol; 2009 Mar; 301(1-2):97-103. PubMed ID: 19022338
[TBL] [Abstract][Full Text] [Related]
20. Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease.
Bauman DR; Steckelbroeck S; Williams MV; Peehl DM; Penning TM
Mol Endocrinol; 2006 Feb; 20(2):444-58. PubMed ID: 16179381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
